These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 22172020

  • 1. Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis.
    Samouilidou EC, Karpouza AP, Kostopoulos V, Bakirtzi T, Pantelias K, Petras D, Tzanatou-Exarchou H, J Grapsa E.
    Ren Fail; 2012; 34(2):160-4. PubMed ID: 22172020
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum oxidized LDL is inversely associated with HDL2-cholesterol subclass in renal failure patients on hemodialysis.
    Samouilidou E, Karpouza A, Grapsa E, Tzanatou-Exarchou H.
    Nephron Clin Pract; 2010; 115(4):c289-94. PubMed ID: 20424480
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Dyslipidemia in patients being treated with peritoneal dialysis].
    Zharfbin A.
    Vnitr Lek; 2006 Nov; 52(11):1051-7. PubMed ID: 17165524
    [Abstract] [Full Text] [Related]

  • 6. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND, Norris K.
    Blood Purif; 2011 Nov; 31(1-3):189-96. PubMed ID: 21228589
    [Abstract] [Full Text] [Related]

  • 7. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M, Tazza L, Merki E, Giungi S, Luciani G, Miller ER, Lin EB, Tortorelli A, Tsimikas S.
    Blood Purif; 2007 Nov; 25(5-6):457-65. PubMed ID: 18075247
    [Abstract] [Full Text] [Related]

  • 8. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI, Schreier L, Elbert A, Berg G, Beresan H, López G, Wikinski R.
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I, Smaoui W, Hamida FB, Ouniss M, Aderrahim E, Hedri H, Elyounsi F, Maiz HB, Abdallah TB, Kheder A.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [Abstract] [Full Text] [Related]

  • 10. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
    Arikan H, Koc M, Sari H, Tuglular S, Ozener C, Akoglu E.
    Ren Fail; 2007 Jan; 29(6):713-9. PubMed ID: 17763167
    [Abstract] [Full Text] [Related]

  • 11. Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio - are they real oxidative stress markers in dialyzed patients?
    Pawlak K, Mysliwiec M, Pawlak D.
    Life Sci; 2013 Mar 12; 92(4-5):253-8. PubMed ID: 23295961
    [Abstract] [Full Text] [Related]

  • 12. Correlation between oxidized low-density lipoprotein and other factors in patients on peritoneal dialysis.
    Futatsuyama M, Oiwa T, Komatsu Y.
    Adv Perit Dial; 2002 Mar 12; 18():192-4. PubMed ID: 12402617
    [Abstract] [Full Text] [Related]

  • 13. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H.
    Arterioscler Thromb Vasc Biol; 2005 Dec 12; 25(12):2615-22. PubMed ID: 16195474
    [Abstract] [Full Text] [Related]

  • 14. Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene.
    Ribeiro S, Faria Mdo S, Silva G, Nascimento H, Rocha-Pereira P, Miranda V, Vieira E, Santos R, Mendonça D, Quintanilha A, Costa E, Belo L, Santos-Silva A.
    Hemodial Int; 2012 Oct 12; 16(4):481-90. PubMed ID: 22515595
    [Abstract] [Full Text] [Related]

  • 15. Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.
    Papadea P, Kalaitzopoulou E, Skipitari M, Varemmenou A, Papasotiriou M, Papachristou E, Goumenos D, Grune T, Georgiou CD.
    Redox Biol; 2023 Aug 12; 64():102762. PubMed ID: 37302344
    [Abstract] [Full Text] [Related]

  • 16. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H, Pahl MV, Elahimehr R, Vaziri ND.
    Transl Res; 2009 Feb 12; 153(2):77-85. PubMed ID: 19138652
    [Abstract] [Full Text] [Related]

  • 17. Plasma concentrations of non-esterified fatty acids in chronic renal failure in the United Arab Emirates.
    Gillett MP, Obineche EN, Khan ST, Abdulle AM.
    Saudi Med J; 2004 Nov 12; 25(11):1611-6. PubMed ID: 15573187
    [Abstract] [Full Text] [Related]

  • 18. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
    Misra M, Webb AT, Reaveley DA, Doherty E, O'Donnell M, Seed M, Brown EA.
    Adv Perit Dial; 1997 Nov 12; 13():168-73. PubMed ID: 9360675
    [Abstract] [Full Text] [Related]

  • 19. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
    Sjöberg B, Anderstam B, Suliman M, Alvestrand A.
    Am J Kidney Dis; 2006 Jan 12; 47(1):60-71. PubMed ID: 16377386
    [Abstract] [Full Text] [Related]

  • 20. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease.
    Samouilidou E, Pantelias K, Petras D, Tsirpanlis G, Bakirtzi J, Chatzivasileiou G, Tzanatos H, Grapsa E.
    Ther Apher Dial; 2014 Jun 12; 18(3):279-83. PubMed ID: 24119290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.